1. Valeant started the year by selling off $2.1 billion in assets.
2. The company has $30.4 billion in lingering debt. Through selling off strategic assets, however, it avoided paying additional interest on a bond.
3. As of Feb. 24, 2017, Valeant shares were trading at $16.24 per share. The company has a 52-week high of $86.50 and a 52-week low of $13.
More articles on gastroenterology/endoscopy:
LifeBond enrolling patients in LifeSeal surgical sealant study: 4 key notes
GI leader to know: Dr. Sam Moussa of Adobe Gastroenterology
5 ways CMS changes are affecting reimbursement for ASCs, anesthesia practices and providers
